Our guides to Mounjaro on the NHS and Wegovy on the NHS cover the referral pathways in detail
To date, no clear clinical evidence has been found to suggest the tumorigenic effect of GLP-1RAs (226), whereas plenty of studies have indicated that GLP-1RAs can inhibit the growth of ovarian, breast, prostate, and pancreatic cancer (227, 228)
These agents mimic GLP-1, enhancing insulin secretion, suppressing glucagon release, and slowing gastric emptying to improve glycemic control [5], [6], [7]
Among patients without diabetes, the pattern differed from patients with type 2 diabetes: patients on a GLP-1 who maintained a stable weight had a higher osteoporosis risk relative to those who maintained a stable weight on another weight loss medication (22.0% higher for GLP-1 users)
All proceeds from them go to support Scripps Research
How do you start a GLP-1 weight-loss medication